Sandoz Inc. and its Fougera Pharmaceuticals unit have agreed to a $400 million settlement with a coalition of state attorneys general over a conspiracy to fix prices and rig bids on more than 100 generic prescription drugs. The deal, announced October 1, reaches consumers in 48 states plus Washington, D.C., the Northern Mariana Islands, Puerto Rico and the U.S. Virgin Islands. Anyone who paid for one of the listed drugs between May 2009 and December 2019 has until March 8, 2027 to file a claim.
Affiliate links — we may earn a commission.
The March 8, 2027 claim deadline. The news leaves a household to match its own prescriptions to the drug list; The Settlement & Refund Recovery System includes a step-by-step filing walkthrough.
Open the filing walkthrough before the March 8 cutoff →
What Sandoz and Fougera agreed to pay, and over how long
The settlement figure is not a single cash wire. According to the New York attorney general’s account, the total is $400 million, made up of $320,560,180 in principal plus interest paid over seven years. Alongside the money, Sandoz must put an antitrust compliance program in place and hire a Chief Compliance Officer.
The release from New York Attorney General Letitia James describes a “broad, coordinated, and systematic conspiracy” among generic makers to fix prices, avoid competition and rig bids. The affected products span tablets, capsules, creams and ointments, from antibiotics and antidepressants to contraceptives, anti-inflammatories and medicines for diabetes, cancer, epilepsy, multiple sclerosis, HIV and ADHD. Some price increases exceeded 1,000 percent.
The structure implies a large interest component. Subtracting $320,560,180 from $400 million leaves roughly $79.4 million that arrives as interest over the seven-year schedule, so the cash is not all available at once. The compliance terms include annual antitrust training for sales and management staff.
James framed the harm in household terms: “Generic drug price increases make it harder for working families throughout New York to afford the medications they need.” The money is to be distributed to impacted consumers across the coalition states.
The Heritage executives behind the wider case
Sandoz is not the first defendant to settle in this litigation, and the release ties the case to named people. Jeffery Glazer and Jason Malek, both former executives of Heritage Pharmaceuticals, are identified as individuals who settled separately with the states. Six more pharmaceutical executives have settled and are cooperating, and a further 16 senior executives are named across three complaints.
The release describes the litigation in three complaints. The first named 18 corporate defendants, two individuals and 15 generic drugs. A second complaint, filed in 2019, was brought against Teva Pharmaceuticals and 19 other manufacturers and named 16 individual senior executives. A third targets 80 mostly topical generic drugs and names 26 corporate and 10 individual defendants. Glazer and Malek, the release says, have settled and are cooperating, as have six additional executives.
That detail matters for readers because it shows the case is built on individuals as well as corporations. The states’ complaints reach back years, and the Sandoz agreement closes out one of the larger corporate defendants while other cases continue against other companies.
Earlier settlements already feed the same claim process
The same release lists three earlier deals: Apotex and Heritage at $49.1 million in November 2024, Lannett and Bausch at $17 million in February 2026, and Glenmark at more than $29 million in July 2026. Those payments and the Sandoz money are all headed to consumers through the one claim site, www.AGGenericDrugs.com, which also lists a phone line at 1-866-290-0182. Added together, the three earlier deals come to about $95 million, and with Sandoz the coalition’s announced recoveries pass $495 million. A separate September 22 notice from the same office urged New Yorkers to file.
Which purchases count
Eligibility turns on a list. A consumer qualifies to file only if the person purchased a generic prescription drug that appears on the settlement website’s drug list during the window from May 2009 through December 2019. A claim form is required; nothing is paid automatically on the strength of the announcement.
The release does not say how the $400 million will be divided, how many consumers are expected to file, or what any individual payment might be. Those figures depend on how many valid claims come in. Until the administrator publishes a per-claim amount, any figure floating around for a household is a guess.
A ten-year purchase window and a drug list that runs past 100 names
The practical difficulty is the match. A household has to work out which of its own prescriptions are on a list covering more than 100 drugs, and which of those were bought in which years between May 2009 and December 2019. For a long-term medication, that can be a decade of fills at one or several pharmacies.
Records that old are rarely sitting in a drawer. Pharmacy portals, insurer explanation-of-benefits statements and old receipts are the usual places to look, and the settlement website is where the release says the drug list lives. Anyone filing for a parent or a late spouse faces the same lookup with fewer records.
The official route requires nothing beyond the claim itself: the claim site at www.AGGenericDrugs.com and the phone line in the attorney general’s release are the way to file, and the March 8, 2027 deadline applies either way. The attorney general’s press release index is where any later notice on the claims process would appear.
A paid service for keeping open settlements in one list
Generic-drug claims are one of many settlement windows that run at the same time, each with its own form and cutoff. MoneyPilot is a paid subscription service that lists open class-action settlements and shows which ones may match a member’s situation. It also files claim forms for members and tracks deadlines and payout status.
Click here to see how MoneyPilot lists open settlements →
This article was drafted with AI assistance and checked against the New York Attorney General’s published releases.
